Literature DB >> 22242060

Catastrophic cerebral antiphospholipid syndrome presenting as cerebral infarction with haemorrhagic transformation after sudden withdrawal of warfarin in a patient with primary antiphospholipid syndrome.

Abdul Majid Wani1, Waleed Mohd Hussain, Mousa Ali Al Mejally, Khaled Shawkat Ali, Sadeya Hanif Raja, Wael Al Maimani, Mazen G Bafaraj, Ashraf Bashraheel, Mubeena Akhtar, Amer Mohd Khoujah.   

Abstract

Catastrophic antiphospholipid syndrome (APS) is caused by thrombotic vascular occlusions that affect both small and large vessels, producing ischaemia in the affected organs. The "catastrophic" variant of the antiphospholipid syndrome (cAPS) develops over a short period of time. Although patients with cAPS represent <1% of all patients with APS, they are usually life threatening with a 50% mortality rate. A strong association with concomitant infection is thought to act as the main trigger of microthromboses in cAPS. Several theories have been proposed to explain these physiopathological features. Some of them suggest the possibility of molecular mimicry between components of infectious microorganisms and natural anticoagulants, which might be involved in the production of cross-reacting antiphospholipid antibodies. We present a case of catastrophic cerebral APS characterised by massive temporal lobe infarction and subsequent haemorrhagic transformation after sudden withdrawal of warfarin.

Entities:  

Year:  2010        PMID: 22242060      PMCID: PMC3028224          DOI: 10.1136/bcr.09.2009.2243

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Delineation of lateral tentorial sinus with contrast-enhanced MR imaging and its surgical implications.

Authors:  Zinat Miabi; Ramin Midia; Suzan E Rohrer; Ellen G Hoeffner; Robert Vandorpe; Caglar M Berk; Mehran Midia
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

2.  Catastrophic primary antiphospholipid syndrome presenting as status epilepticus.

Authors:  L J Coward; D M Kullmann; N P Hirsch; R S Howard; S B Lucas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

Review 3.  The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence.

Authors:  Oscar-Danilo Ortega-Hernandez; Nancy Agmon-Levin; Miri Blank; Ronald A Asherson; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2008-12-06       Impact factor: 7.094

Review 4.  Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors.

Authors:  Gerard Espinosa; Silvia Bucciarelli; Ronald A Asherson; Ricard Cervera
Journal:  Semin Thromb Hemost       Date:  2008-04       Impact factor: 4.180

5.  Catastrophic antiphospholipid syndrome in the central nervous system.

Authors:  Min-Nung Huang; Song-Chou Hsieh
Journal:  J Rheumatol       Date:  2009-03       Impact factor: 4.666

6.  Massive cerebrovascular infarct due to the catastrophic antiphospholipid syndrome in a patient with idiopathic thrombocytopenic purpura.

Authors:  Ariel Modrykamien; Anita Reddy; Jorge A Guzman; Samar Farha
Journal:  J Intensive Care Med       Date:  2009 Jul-Aug       Impact factor: 3.510

Review 7.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Rebound after cessation of oral anticoagulant therapy: the biochemical evidence.

Authors:  U Genewein; A Haeberli; P W Straub; J H Beer
Journal:  Br J Haematol       Date:  1996-02       Impact factor: 6.998

9.  [Splenic infarction after warfarin discontinuation during atrial fibrillation].

Authors:  M Trappolini; A Scorzai; V Loguercio; M Stoppo; A Sebastianelli; M Iannotta; F Del Porto; M Proietta; G Aliberti
Journal:  Clin Ter       Date:  2008 Nov-Dec

10.  A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

Authors:  D Erkan; Y Yazici; M G Peterson; L Sammaritano; M D Lockshin
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

View more
  1 in total

1.  Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review.

Authors:  Melody Hermel; David Hermel; Saif Azam; Jerold Shinbane; Annahita Sarcon; Erika Jones; Arjun Mehta; Luanda Grazette; Howard Liebman; Ilene Weitz
Journal:  EJHaem       Date:  2020-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.